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ABSTRACT 
Objectives: Genetic testing of cancer predisposing genes will increasingly be needed in 
oncology clinics in order to target cancer treatment. This Delphi study aimed to identify areas of 
agreement and disagreement between genetics and oncology health professionals and service 
users about the key messages required by women with breast/ovarian cancer who undergo 
BRCA1/BRCA2 genetic testing and the optimal timing of communicating key messages.  
Methods:  Participants were 16 expert health professionals specialising in oncology/genetics and 
16 service users with breast/ovarian cancer and a pathogenic BRCA1/BRCA2 variant. On-line 
questionnaires containing 53 inductively developed information messages were circulated to the 
groups separately.  Participants rated each message as key/ not key on a Likert scale and 
suggested additional messages.  Questionnaires were modified according to the feedback and up 
to three rounds were circulated. Consensus was reached when there was ≥75% agreement. 
Results: Thirty key messages were agreed by both groups with seven of the key messages 
agreed by ≥95% of participants: dominant inheritance, the availability of predictive testing, the 
importance of pre-test discussion, increased risk of breast and ovarian cancer and the option of 
risk reducing mastectomy and bilateral salpingo-oophorectomy. Both groups agreed that key 
messages should be communicated pre- and post genetic testing.  
Conclusions: There was a high level of agreement within and between the groups about the 
information requirements of women with breast/ovarian cancer about BRCA1/BRCA2.  These 
key messages will be helpful in developing new approaches to the delivery of information as 
genetic testing becomes further integrated into mainstream oncology services.  
 
Key words: key messages, BRCA1/BRCA2, breast/ ovarian cancer, pre/post genetic test 
information, oncology/ genetics health professionals, genetic testing  
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BACKGROUND 
There is consensus in the UK that the current system of providing cancer genetic testing through 
specialist genetics services does not have the capacity to meet the demand raised by advances in 
genomic medicine 1. Genetic testing and the delivery of information about cancer predisposing 
genes for cancer patients will therefore increasingly need to take place in the oncology clinic. 
The findings from this study, investigating agreement and disagreement amongst oncology and 
genetics health professionals and service users about the information required by women with 
breast or ovarian cancer about BRCA1/BRCA2 testing, will be helpful in informing current and 
future clinical practice. 
  
 Several studies have investigated the information communicated during genetic 
counselling about BRCA1/BRCA2 variants 2 3 4.  Women with cancer have more unmet 
information needs following genetic counselling than women without cancer 5. Women 
undergoing genetic testing shortly after diagnosis to facilitate treatment decisions prefer brief 
cancer risk information without statistics and hope-giving information about options to address 
the risks 6,7.  
  
 There are differences in the approach, focus and training of health professionals 
specialising in oncology and genetics which are likely to impact on the information 
communicated. Clinical genetics focuses the family and involves information exchange and the 
provision of support 8. Oncology focuses on the individual 9 and initiation of treatment. 
Oncology health professionals are not always confident in genetic risk assessment 10, may be 
concerned about causing distress by genetics referral 11, are not always clear about who is 
responsible for making referrals 12 and do not consistently refer patients even if they have been 
identified 13-15.   
  
Clinical guidelines recommend pre-test genetic counselling to enhance patients’ understanding 
of the implications of testing for themselves and their families and to enable informed consent 
16,17. Not having pre and post-test counselling has been associated with negative outcomes 18.  
Post-test counselling with affected women has been shown to significantly increase the 
proportion of at risk relatives who make contact with a genetics service 19. However, non-
genetics heath professionals ordering genetic tests in the USA frequently do not schedule a pre-
test counselling session 20.  
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As the issues around genetic testing become increasingly complex, it will be important to 
develop tailored and streamlined protocols for pre and post-test counselling. This study aimed to 
investigate areas of agreement and disagreement between expert health professionals and service 
users about the messages required by affected women about BRCA1/ BRCA2 and the timing of 
communicating key messages.   
 
 
METHODS 
Design: The study design was a Delphi consensus exercise 21 with health professionals and 
service users who had expert professional or personal experience in this field.  The Delphi 
consensus method involves several rounds of survey with a group of experts who anonymously 
respond and then receive feedback on the group response before being sent a subsequent survey 
to complete. The goal is to reduce the range of responses with a view to achieving consensus 22.  
 
Developing the questionnaire: An earlier study 23 identified the information communicated 
during genetic counselling with affected women following identification of a pathogenic 
BRCA1/BRCA2 variant. A key message was defined as: ‘information required by the 
individual with cancer in order to understand the risks, implications and options for 
themselves and their relatives and to decide on a course of action that is appropriate for them’. 
This definition was derived from the cognitive and behavioural aspects of the definition and 
published goals of genetic counselling 24 and refined, together with criteria to assist with 
focusing on the definition, in a pilot study with eight expert genetics health professionals. The 
questionnaire was developed using the Qualtrix software and tested for comprehension, 
readability and usability by a genetics health professional, an oncology health professional 
and a service user (the study interest group).    
  
Participants: Purposive sampling methods were used to identify 16 health professionals with 
expert knowledge and 16 service users with breast/ovarian cancer and personal experience of 
diagnostic testing for BRCA1/BRCA2 variants within the National Health Service (NHS). The 
sample size was selected in order to recruit an appropriately experienced expert group of health 
professionals and an equivalent number of service users. Service users were required to be 
female and to have had breast or ovarian cancer and a pathogenic BRCA1/BRCA2 variant 
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identified after publication of the NICE guidelines for familial breast cancer 25.  All participants 
were required to have an interest in the topic, the capacity, willingness and time to take part, be 
accessible by email and able to communicate in English.  
 
Health professionals were identified by personal contact, recommendation of senior colleagues 
or participation at a senior level in relevant UK professional organisations, such as the UK 
Cancer Genetics Group or BASO – The Association for Cancer Surgery. Approach was made by 
personal email and study information was provided. Return of the questionnaire was accepted as 
consent to take part.     
 
Service users were identified via UK voluntary organisations that provide support and 
information for BRCA1/BRCA2 carriers. Potential participants who expressed an interest were 
telephoned to explain the study, determine eligibility and answer any questions. Eligible 
participants were sent a participant information sheet and consent form.  
 
Sample: Health professionals were four clinical geneticists, four genetic counsellors, two 
clinical nurse specialists, two gynaecological oncologists, two breast surgeons and two clinical 
oncologists.  All health professionals worked within multidisciplinary teams in teaching 
hospitals. All genetics health professionals worked in consultant/senior positions within regional 
genetics centres, counselling/managing affected women about a pathogenic BRCA1/BRCA2 
variant at least once a week. Six of the oncology health professionals worked in consultant/senior 
positions and two were sub-specialty doctors in the last year of training. Seven of the oncology 
health professionals managed/cared for/counselled affected women at least once a month and 
one discussed genetics referral two to three times a week (shown in Supplementary table 1). All 
16 participants completed the round 1 questionnaire. One geneticist and one clinical oncologist 
did not continue beyond round 1. The other 14 health professionals continued with the study.    
 
Of the 16 service users, five were BRCA1 carriers and 11 were BRCA2 carriers. The mean age 
was 53 (range 43 to 69 years):  nine had breast cancer, three had ovarian cancer and four had 
breast and ovarian cancer. Two participants were tested immediately after diagnosis and 14 
underwent testing after treatment. Ten participants were educated to degree level or above, six 
completed education between age 16 and 18 (shown in Supplementary table 2). Sixteen 
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participants completed the round 1 questionnaire, 14 completed round 2 and 12 completed round 
3.    
Procedure: Ethics approval was granted. Data were collected between November 2013 and 
October 2014.  
 
The questionnaire included information about the purpose of the study, the definition of a key 
message and the information messages. The data were analysed separately for each group. The 
questionnaire was amended at each round according to the data from the previous round. An 
agreement level of ≥75% was selected 26. At each round, messages agreed as key or not key were 
removed from circulation. Remaining messages were re-circulated up to three times or until 
agreement was reached. Messages that did not reach agreement were circulated together with the 
median score, range of responses and summarised anonymised comments. The neutral option 
was removed after the first circulation of each message in order to increase positive or negative 
responses. 
 
Participants were asked to decide if each message was key or not key using a 5-point Likert scale 
with options ranging from ‘a key message’ to ‘not a key message’. Messages with a definite 
response were scored higher than those with a less definite response in order to capture the 
extent of certainty about the message.  
 
The first time a message was circulated, comments were invited on the wording of the message, 
the reasons for selection and potential additional key messages.  For feasibility, changes to 
wording and suggested additional messages were accepted when suggested by two or more 
participants or for consistency with other messages.   
 
For messages assessed as key/ probably key, participants were asked to decide whether the 
message should be communicated, before testing, once a pathogenic variant has been detected, at 
both times or at another time altogether. Each response was equally rated as 1.    
 
Analysis: The mean score and its standard deviation (SD) for each message at each round and 
for each group was calculated using these functions in SPSS. The final mean score and SD for 
each message was calculated once agreement was reached or, for messages where no agreement 
was reached, at the end of round 3. Where participants did not continue, their last recorded score 
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was counted as their final score. Mean scores for each group were organised in descending order, 
enabling identification of messages with ≥75% agreement as key or not key messages and those 
where no agreement was reached, messages where no agreement was reached.  
 
The number of messages circulated and agreed as key or not key at each round was documented 
for each group.  
 
Analysis of the timing of communication involved identifying the number and percentage of 
responses in each time point for key messages. Agreement was reached when there was ≥75% 
agreement about the timing of communication of the key message. 
 
 
RESULTS 
Key messages: Health professionals agreed on 34 key messages and 18 messages that were not 
key. The key messages are shown in Supplementary table 3). There was no agreement about 11 
messages.   
 
Service users agreed on 35 key messages and 11 messages that were not key (shown in 
Supplementary table 4). There was no agreement about 17 messages.  
 
Health professionals and service users agreed on 30 key messages. These key messages are 
shown in abbreviated form in Table 1. (The full wording of all key messages is available in 
Supplementary tables 3 and 4).   
 
Seven key messages reached ≥ 95% agreement amongst both groups. These key messages are 
shown in full in Table 2. Both groups agreed that 10 messages were not key.  There was 
disagreement between the groups about three messages. These messages are shown in full in 
Table 3.  
  
[Insert Table 1] 
[Insert Table 2] 
[Insert Table 3] 
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There was agreement by one group only about six messages. Health professionals agreed that 
messages about the variant not ‘skipping a generation’, male inheritance and the outcomes of 
diagnostic testing were key messages; there was no agreement amongst the service users about 
these messages. Service users agreed that messages about genetic testing and insurance, the risk 
of male breast cancer and breast awareness were key messages; there was no agreement amongst 
the health professionals about these messages. These data are shown in Supplementary tables 3 
and 4. 
 
Reaching agreement: Fifty-three messages were circulated in round 1 and a further 10 were 
added in round 2. Health professionals agreed on 21/34 key messages (62%) the first time the 
message was circulated, 5/34 (14.5%) the second time and 8/34 (23.5%) the third time.   
 
Service users agreed on 23/35 key messages (66%) the first time the message was circulated; 
4/35 (11%) the second time and 8/35 (23%) the third time.  
 
Health professionals and service users agreed on 14/30 key messages (47%) the first time the 
message was circulated, 6/30 (20%) the second time and 10/30 (33%) the third time. Neither 
group reached agreement about eight messages. 
 
Timing of communicating key messages: Health professionals agreed on the timing of 
communicating 18/34 (53%) key messages. For 17/18 of these, it was agreed that the optimal 
timing of communication is before testing and once a pathogenic variant has been identified. It 
was agreed that the message about specifying the name of the gene involved should be 
communicated only once a pathogenic variant has been identified.  
 
Service users agreed on the timing of communicating 25/35 (71%) key messages. For all of these 
key messages it was agreed that the optimal timing of communication is before genetic testing 
and once a variant has been identified.  
 
Health professionals and service users agreed that 13/30 (43%) key messages should be 
communicated before genetic testing and once a variant has been identified. 
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DISCUSSION 
The high level of agreement within the health professionals’ group suggests shared professional 
knowledge between oncology and genetics health professionals despite differences in training, focus 
and approach. This is reassuring given the need for closer integration between oncology and genetics 
services. The high level of agreement between service users and health professionals suggests 
consistency in the information provided during genetic counselling in the UK as lay understandings 
are inclined to incorporate medical concepts and ideas, even if the form of the knowledge changes 
slightly 27. This, together with raised general awareness about hereditary breast and ovarian cancer 
over recent years 28, may have contributed to the high level of agreement overall. 
The messages where there was disagreement between the groups and those agreed as key 
messages by one group only, suggest differences in the prior knowledge and priorities of the 
groups. The messages agreed as key messages by only the health professionals group refer to the 
potential implications of testing and inheritance, some of which are included within the NICE 
guidelines for familial breast cancer 16. These messages may not have been obviously relevant to 
the service users, given that concepts of inheritance are constructed from family experience and 
relationships 29. Consistent with research indicating that cancer patients prefer to be fully 
informed about their illness 30 31, the messages agreed as key by only the service users group 
refer to information that empowers women to take action to protect themselves and their 
families, raising awareness and providing hope, even in the absence of clear evidence or 
surveillance. The health professionals may have been mindful of the relationship between the 
amount of information given and the proportion recalled 32 and wanted to manage the volume 
and complexity of the information communicated by focusing on information of relevance to 
affected women.   
Amongst both groups, the majority of key messages were agreed the first time they were 
circulated. The findings of this study are validated by the ease of reaching agreement within and 
between the groups and the high response and retention rate.   
For the key messages where timing of communication was agreed, ‘before genetic testing and 
once a variant has been detected’ was the most popular choice. These findings highlight the 
value placed by service users with cancer on pre and post-test communication of genetic 
information. 
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Study limitations: This study did not address the specific information needs of unaffected 
women undergoing genetic testing, affected women undergoing treatment-focused or multi-gene 
panel testing, affected men, the post-test information needs of affected women who do not have a 
BRCA1/BRCA2 variant or how and by whom the information is best communicated. Other 
studies have demonstrated effective delivery of pre-test information about genetic testing for 
BRCA1/BRCA2 using written33, digital, telephone-based 34 and DVD-based communication 34,35. 
As the messages were developed inductively from post-test genetic counselling consultations, 
some messages recommended by clinical guidelines 16 ,  such as the meaning of a ‘no mutation 
detected’ result, the timescale of results and confidentiality, were not included in the 
questionnaires. Participants were invited to suggest additional messages in order to overcome 
this potential issue. However, two or more participants did not suggest that these were key 
messages. Similarly, some messages, such as the importance of multidisciplinary team 
involvement and the availability of psychological support, did not reach agreement as key or not 
key by either group. Finally, the small sample size and heterogeneity of the groups may limit 
generalizability of these findings.   
 
Clinical implications:  The key messages identified in this study are not intended as a didactic 
list; some messages will not be relevant to all women and some women will want more or less 
information. However, the key messages do provide a guide for communicating with affected 
women about BRCA1/BRCA2 genes and are a reminder that some information considered key by 
health professionals may not be considered key by women with cancer and vice versa.  
 
Health professionals need to remain up to date with changes that may affect the key messages 
and carefully explain the nuances of the messages. This is highlighted by the recent challenge to 
the evidence regarding breast cancer risk reduction associated with risk reducing bilateral 
salpingo-oophorectomy 36-38.  
 
Where time or the ability to assimilate information is limited, for example for women 
undergoing testing to determine cancer treatment, the messages with the highest level of 
agreement provide a minimum set of key messages to communicate: dominant inheritance, the 
availability of predictive testing, the importance of pre-test discussion, increased risk of breast 
and ovarian cancer and the option of risk reducing mastectomy and bilateral salpingo-
oophorectomy. 
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Drawing on current practice and expert opinion, this study has provided evidence of the key 
messages required by affected women about BRCA1/BRCA2 and the optimal timing of 
communication. The findings will be helpful in developing new approaches to the delivery of 
information as genetic testing becomes further integrated into mainstream oncology services.  
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Table 1. Key messages agreed by ≥75% of health professionals and service users 
(BC breast cancer, OC ovarian cancer, FTC fallopian tube cancer, PPC primary peritoneal 
cancer, PC prostate cancer, RRM risk reducing mastectomy, CM contralateral mastectomy, 
RRBSO risk reducing salpingo-oophorectomy) 
 
BRCA1/BRCA2 gene faults are dominantly inherited.  
Identifying the side of the family at risk is important. 
A BRCA1/BRCA2 gene fault may explain the family history. 
The fault is in the BRCA1/BRCA2 gene (specify). 
Cancer is not inevitable for carriers. 
Predictive testing is available for relatives once a fault has been detected.  
Women at 50% risk of a BRCA1/BRCA2 gene fault are eligible for high-risk breast screening.  
Inform all at risk relatives that genetic testing is available. 
Discussing the implications and possible outcomes prior to testing is important. 
The decision to be tested is up to each individual.  
Female BRCA1/BRCA2 carriers with BC are at increased risk of further primary BC. 
Female BRCA1/BRCA2 carriers with OC/FTC are at increased risk of BC. 
Female BRCA1/BRCA2 carriers with breast cancer are at increased risk of OC/FTC. 
Female BRCA1/BRCA2 carriers without cancer are at increased risk of breast cancer. 
For female BRCA1/BRCA2 carriers the risk of BC between age 25 and 30 may be increased. 
Most of the risk occurs after age 30.    
Female BRCA1/BRCA2 carriers without cancer are at increased risk of OC, FTC and PPC.  
For female BRCA1 carriers the risk of OC before age 40 may be increased. Most of the risk 
occurs after age 40. For female BRCA2 carriers most of the risk occurs after age 45. 
Male BRCA1/ BRCA2 carriers are at increased risk of PC. The risk is higher in BRCA2 than 
BRCA1. 
RRM is an option for female BRCA1/BRCA2 carriers. 
Breast reconstruction is an option after mastectomy. 
RRM reduces the risk of BC (but a small risk remains). 
Annual breast screening is available from age 30 for female BRCA1/BRCA2 carriers.  
There are limitations to breast screening.  
Ovarian screening is not effective or available. Women with symptoms should see their GP.    
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Once the risk of ovarian cancer starts to rise, RRBSO is an option for female BRCA1/BRCA2 
carriers.  
RRBSO reduces the OC/FTC risk (but a small risk of PPC remains). 
RRBSO before the natural menopause may reduce the risk of primary BC by up to 50% in 
unaffected BRCA2 carriers. * 
BSO will result in menopause.  
Genetic testing may provide helpful risk and management information for female 
BRCA1/BRCA2 carriers with cancer. 
RRM or CM will reduce the risk of a new primary BC but will not reduce the risk of 
metastases from the initial cancer. 
* Wording amended to reflect challenges to earlier evidence 36-38  
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Table 2. Key messages agreed by ≥95% of health professionals and service users  
 
The children of a person with a BRCA1/BRCA2 gene fault each have a 50% (1 in 2) risk of 
inheriting the gene fault. 
Predictive (targeted) genetic testing is available for relatives once a BRCA1/BRCA2 gene fault 
has been identified. This will show whether or not the person has inherited the known faulty 
gene, and so predicts whether they might be at risk (this is called a predictive test). 
Before having a genetic test it is important to discuss the implications and possible outcomes.  
Breast cancer risk is increased for women without cancer who have a BRCA1/BRCA2 gene 
fault.  
For women who have a BRCA1/BRCA2 gene fault, ovarian cancer (including fallopian tube 
and primary peritoneal cancer) risk is increased. 
Risk Reducing Mastectomy (surgery to remove the breasts in order to reduce the risk of 
cancer) is an option for women who have a BRCA1/BRCA2 gene fault. 
Once the risk of ovarian cancer starts to rise, Risk Reducing Bilateral Salpingo-Oophorectomy 
(surgery to remove the ovaries and fallopian tubes in order to reduce the risk of cancer) is an 
option for women who have a BRCA1/BRCA2 gene fault. 
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Table 3. Areas of disagreement between health professionals and service users 
 
 Health professionals  
 
 
 
 
 
 
 
 
 
 
Service 
users  
  
 
Key message Not key 
Key    A BRCA2 gene fault may slightly 
increase the risk of other cancers, 
such as pancreatic, gall bladder and 
bile duct cancer. However, the risks 
are small and there is no screening 
available. 
Diet and lifestyle can make a 
difference to the risk of cancer 
generally but the impact is likely to 
be small compared with the risk 
associated with the BRCA1/BRCA2 
gene fault. 
Not key If a person does not inherit a 
known BRCA1 or BRCA2 gene 
fault, their risks of breast/ 
ovarian/ prostate cancer will be 
similar to other people in the 
general population. 
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